Finance

Lists
ONCY:NASDAQ
Oncolytics Biotech Inc
$ 0.75
-5.11%
(-0.040) 1D
$ 0.75
-0.21% (-0.0016)
After hours
Closed: 7-р сарын 29, 16:00:00 (GMT-4)  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ONCY...
Open
$ 0.78
High
$ 0.79
Low
$ 0.74
Mkt. cap
89.94 сая
Avg. vol.
1.46 сая
Volume
0.00
52-wk high
$ 1.51
52-wk low
$ 0.74
Beta
1.09
Shares outstanding
119.35 сая
No. of employees
29
Open
$ 0.78
High
$ 0.79
Low
$ 0.74
Mkt. cap
89.94 сая
Avg. vol.
1.46 сая
Volume
0.00
52-wk high
$ 1.51
52-wk low
$ 0.74
Beta
1.09
Shares outstanding
119.35 сая
No. of employees
29
News stories
From sources across the web
Profile
Oncolytics Biotech Inc. is a biotech company headquartered in San Diego, California, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. Wikipedia
About Oncolytics Biotech Inc
CEO-
Employees29
Founded1998
HeadquartersКалгари, Альберта, Канад
Sector-
Websiteoncolyticsbiotech.com
Analyst ratings
Based on 4 analysts giving stock ratings to ONCY in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for ONCY in the last 3 months.
Highest
Current $ 0.75
$ 10.00 (+1,230.49%)
Average
$ 6.00 (+698.30%)
Lowest
$ 3.00 (+299.15%)
Analyst
Recommendation
Action
Price target
Projected
Date
Boris Peaker
JonesTrading
Hold
Maintained
-
-
07/13/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$ 10.00
+1,230.5%
07/13/2026
Chad Messer
Lake Street
Buy
Maintained
$ 5.00
+565.2%
06/01/2026
Jason McCarthy
Maxim Group
Buy
Reiterated
$ 3.00
+299.1%
05/21/2026
Soumit Roy
JonesTrading
Hold
Maintained
-
-
04/06/2026
Previous reportsAll values in CAD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CAD
2024 оны 12-р сар
2025 оны 3-р сар
2025 оны 6-р сар
2025 оны 9-р сар
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
-
-
2.81 сая
7.52 сая
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
-
2.90 сая
6.32 сая
Operating expense
-
-
5.71 сая
13.84 сая
Total operating expenses
-
-
5.71 сая
13.84 сая
Operating income
-
-
-5.71 сая
-13.84 сая
Other non operating income
-
-
-196.00 мян
-1.05 сая
EBT including unusual items
-
-
-6.08 сая
-14.65 сая
EBT excluding unusual items
-
-
-6.08 сая
-14.65 сая
Income tax expense
-
-
85.00 мян
-252.00 мян
Effective tax rate
-
-
-1.40%
1.72%
Other operating expenses
-
-
-
-
Net income
-
-
-6.16 сая
-14.40 сая
Net profit margin
-
-
-
-
Earnings per share
-0.10
-0.08
-0.07
-0.14
Interest and investment income
-
-
104.00 мян
100.00 мян
Interest expense
-
-
-
-
Net interest expenses
-
-
104.00 мян
100.00 мян
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-5.68 сая
-13.82 сая
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer